Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-12P is a processed pseudogene derived from the U6 small nuclear RNA gene family. U6 small nuclear RNA itself is a core component of the spliceosome, required for the removal of pre-mRNA introns by catalyzing splicing activity through complex RNA-RNA and RNA-protein interactions. However, RNU6-12P does not encode a functional product and is thought to be an evolutionary remnant with no known biological function. Pseudogenes like RNU6-12P are common in vertebrate genomes, particularly among small nuclear RNA families, and may serve as evolutionary markers of retrotransposition dynamics rather than active biological agents. The presence of an extensive collection of U6-derived pseudogenes in the genome highlights the evolutionary importance of U6 snRNA, but these pseudogenes themselves are not functional or clinically relevant targets for pharmacological modulation.
Null; not applicable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 12, pseudogene (RNU6-12P).